Seeking Alpha


Send Message
View as an RSS Feed
View shel113's Comments BY TICKER:
Latest  |  Highest rated
  • MannKind And Afrezza's NDA Evaluation: What Is The Real Justification For The Advisory Committee? [View article]
    Thank you for your reply to me. I understand that we are past phase III where Afreeza should have proved itself as a viable drug. My comment was based on the authors writeup and I may have not understood that he was simply expressing a norm versus a problem. I personally am rooting for an effective oral drug for diabetics but the FDA seems to have had a historical issue with this medication. Today another author discussed the briefing document and expressed a number of concerns which could derail approval. I personally would not use Afrezza if approved until a number of years have passed and this drug proves itself over time in the general population. I would also like to see biopies of users after a year or two to evaluate how this powder effects lung tissue.
    Mar 31, 2014. 01:53 PM | Likes Like |Link to Comment
  • MannKind And Afrezza's NDA Evaluation: What Is The Real Justification For The Advisory Committee? [View article]
    "I think they know how it works" Not according to the write up we are discussing.
    Mar 27, 2014. 11:56 PM | 2 Likes Like |Link to Comment
  • MannKind And Afrezza's NDA Evaluation: What Is The Real Justification For The Advisory Committee? [View article]
    If what you claim is a minor shortcoming, that at present it is not known how effective the actual dosing will be until the drug is approved and futrther studies take place AFTER it comes to market, then how in hell can this drug be approved? How much powder will actually be required to be inhaled for the proper dosing of each patient based on a number of variables? Your write up clearly states that this medication will replace a number of required injections per day of insulin which means we are dealing with people who have a very significant diabetic issue. You seem to be implying that the FDA will allow playing with peoples health as Mankind figures out dosing. Am I misunderstanding your statement?
    Mar 27, 2014. 10:38 PM | Likes Like |Link to Comment
  • A Fresh Dose Of Reality From InVivo [View article]
    I too would like to see the link to the call in June to exit this stock. Possibly on Twitter? I failed to see a write up on SA.
    Aug 29, 2013. 12:09 PM | Likes Like |Link to Comment
  • A Fresh Dose Of Reality From InVivo [View article]
    "A bit of a disappointment"? This is like Hitler's Generals telling him as the Russians and American Armies were banging on his bunker that things will be looking up very soon. What I find interesting is that a new CEO comes in and the next day is able to announce that the time line for a possible viable product has been extended more then three years. Evidently this information was known by many in the company but was kept secret for quite a while while the stock was run up and manipulated. There should be a criminal investigation by the SEC and stock sales investigated for insider trading.
    Aug 28, 2013. 01:00 PM | 1 Like Like |Link to Comment
  • Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common stock and warrants for an unspecified amount. The company intends to use the net proceeds to conduct ongoing clinical trials for NeuVax and its Folate Binding Protein-E39. Piper Jaffray is acting as the sole book-running manager for the offering. [View news story]
    I have been watching this stock for a while and the recent news and analysts write ups have been almost too good to be true. I believe this is a solid company with excelleent potential and I have been perplexed by the drop in the stocks value by about one third in the last 10 days or so. It is now evident that this common stock offering that will water down the value of the stock had been leaked and many individuals have been dumping the stock in anticipation of todays news. This stock will be offered a severe discount to its' recent price and it may be a very good opportunity to purchase it at the lower levels. Personally I think there should be two investigations, one to look at the people who dumped this stock over the last two weeks and the second to see if this stock was manipulated to make it run up to about $2.40 a share .
    Dec 17, 2012. 05:17 PM | 1 Like Like |Link to Comment
  • Neuralstem (CUR +7.2%) spikes, possibly related to a Crain's article reporting "amazing results" in a patient who received 500K stem cells derived by CUR. [View news story]
    Here we go again. "Amazing results" mysteriously finding it's way into the press. True? I would say 99% not, but insiders will and speculaters will do very well unloading. If investers were buying into this strory then the move would be 70% and not 7%.
    Dec 3, 2012. 06:09 PM | Likes Like |Link to Comment
  • Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005 brain cancer drug. Shares -12.2% AH to $1.30. [View news story]
    I sold of my Gern not long after they got out of the Stem Cell business. I mad a few dollars (but got hit when the stock price dived) but the reason for the purchase was buying into a leader in stem cell development. The company seemed to be going downhill and after holing on for some time it was time to hang it up. I am sorry that a company with what appeared to have cutting edge technology (which may yet be developed by Bio Time) has deteriorated to a point where it may cease to exist. I am considering Bio Time as an investment as I still believe that Geron's stem cell technology is very viable and has investment potential.
    Dec 3, 2012. 05:08 PM | Likes Like |Link to Comment
  • Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
    Sorry that you misunderstood my original comment as I clearly stated in the opening statement the the information was "biased and should be considered a solication." My poorly worded followup was simply stating that the author was upfront regarding his position in the company and he was not acting as an impartial analyst.
    Dec 19, 2011. 07:56 PM | Likes Like |Link to Comment
  • Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
    A clarification, when I said "no intent to decieve" this only refers to the position of the person who wrote the article, NOT THE SPEFICIC STATEMENTS CONCERNING THE VIABILITY OF THE COMPANY OR ITS' PRODUCT. The claims made in the article should be viewed critically
    Dec 19, 2011. 02:28 PM | Likes Like |Link to Comment
  • Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
    It was obvious that this article is biased and should be considered a soliciation much like the numerous mailings supposedly issued by "legitimate" newsletters touting a stock which paid them to get people to buy the next hot stock. Seeking Alpha should create standards for allowing articles written by individuals who are "informing" readers concerning their own companies (although one can ask "how many SA articles are bought and paid for?") . A strong caveat should be clearly included for thos reading the article. That being said, I do not believe there was any intent to deceive and if a reader wants to do more research it is his responsibility to do diigence and understand the reality of investing in this type of venture.
    Dec 19, 2011. 02:22 PM | Likes Like |Link to Comment
  • Labopharm Just Became a Great Growth Stock [View article]
    I have gotten very disenchanted with the reports in biomed reports as most of their so called information comes from the shills in the vatious drug companies. I do not trust their impartiality. I have yet to see a stock they have praised to the sky remain at even the original levels after getting a good pop from their pie in the sky reports. Now they are touting RNN and it is moving, maybe this will be the exception. Also when a stock they have written about plummets they completely ignore the issue, and never explain why prices are going down, down, down. DDSS is a stock that I have been wary of for many months. It has been manipulated and many people have been given "inside" information saying this stock will explode. I stayed away from it as my research did not indicate any real value, even when the promise of a time release anti depressent would be approved. If this drug had any real value a major or even minor copany would see it and cut a deal, this did not happen and they were forced to delute the stock value significantly with an offering. The guys manipulating this stock have made tremendous profits as they knew in advance what was going on. The little guys who were being used have lost big time. If the securites commission pulls the sales of this stock they could easily see who was miraculously selling at the top of the market to make big profits. If no company has offered to partner up by now you can be sure this product is dead. This company can not produce and sell this product alone and they do not have a viable prouct . The other "promising" product tramadol time release, is now history.
    Feb 12, 2010. 12:33 PM | 2 Likes Like |Link to Comment